Urothelial Cancer
Follow along on our guide to Urothelial Cancer (UC), an exploration of the latest recommendations and research on diagnosis, treatment, and management of this most common type of bladder cancer. UCs originate in the urothelial cells that line the bladder, as well as the urethra, ureters, renal pelvis, and certain other organs. The cells are also called transitional because they can vary in shape and stretch, and UC is thus also sometimes referred to as transitional cell cancer. Each monthly installment of the Medical Journey will delve into another aspect of urothelial cancer, including possible signs and symptoms, genetic factors, related conditions, treatment options, coping strategies, and lessons learned from unique case studies -- all of which have undergone expert review. Every installment will also include a separate, downloadable, printable information resource for patients.
Urothelial Cancer: Diagnostic Evaluation
–Hematuria often the presenting sign
Patient Handout
For Your Patients: Urothelial Cancer 101
Staging of Urothelial Cancer: Cystoscopy and CT Evaluation Remain Standard
–MRI emerging as adjunctive tool
Patient Handout
For Your Patients: Staging Urothelial Cancer
Non-Muscle-Invasive Bladder Cancer -- Intravesical BCG and Beyond
–Treatment landscape for BCG-unresponsive bladder/urothelial cancer is expanding
Case Study: Recurrence of Urothelial Cancer Challenging in Patient With Morbid Obesity
–Single-docking, robotic-assisted nephroureterectomy proved key; believed to be first report of the approach
The Expanding Role of Immunotherapy for Muscle-Invasive Bladder Cancer
–More treatment paradigms call for immunotherapy when patients are ineligible for or decline to have chemotherapy
Pelvic Lymph Node Dissection During Radical Cystectomy for Muscle-Invasive Bladder Cancer
–Standard approach superior to extended template, associated with fewer toxicities
